纽约学术中心麻醉与重症人员COVID-19暴露与抗体检测前瞻性队列研究
2020年4月对纽约一家大型学术医院麻醉科及附属重症监护人员进行电子邮件调查,评估工作相关COVID-19暴露后症状及抗体情况。105人完成调查(应答率51%),91人完成血清学检测;58%报告至少一次工作相关暴露,其中54%为高风险暴露;暴露者中26.2%报告暴露后COVID-19样症状;抗体阳性率12.1%,有无工作相关暴露者间无差异;抗体阳性与使用纽约地铁通勤及过去90天报告COVID-19样症状相关。
要点
- 工作相关暴露后COVID-19样症状报告率26.2%,抗体阳性率仅12.1%。
- 有无工作相关暴露(含高风险操作)者抗体阳性率无差异(11.8% vs 12.5%)。
- 抗体阳性更常见于使用纽约地铁通勤及过去90天有COVID-19样症状者。
核心结论
- 在疫情震中6-8周内,少数麻醉与重症人员报告工作相关暴露后COVID-19样症状,可检出抗体者更少。
- COVID-19抗体存在似乎与社区/环境传播相关,而非继发于涉及高风险操作的工作暴露。
研究设计与样本
- 前瞻性队列研究,2020年4月15日对哥伦比亚大学欧文医学中心麻醉科及附属重症监护人员发放电子邮件调查。
主要发现
- 报告工作相关暴露的应答者中16人(26.2%)报告暴露后COVID-19样症状,最常见为肌痛(9例)、腹泻(8例)、发热(7例)、咽痛(7例)。
- 91名受检者中11人(12.1%)检出COVID-19抗体,有工作相关暴露者(11.8%)与无暴露者(12.5%)间无差异,包括高风险暴露。
- 抗体阳性者相比抗体阴性者更可能使用纽约地铁通勤上班并报告过去90天COVID-19样症状。
临床怎么用
- 在疫情早期,麻醉与重症人员工作相关暴露后抗体阳性率低,抗体阳性更多与社区暴露相关。
- 应重视社区/环境传播风险,并持续监测工作相关暴露后的症状与抗体状态。
局限性
- 调查应答率51%,可能存在应答偏倚。
- 抗体检测仅限前100名应答者中的91人,样本量有限。
- 工作相关暴露定义为未佩戴足够个人防护装备的任一事件,依赖自我报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Protecting first-line health care providers against work-related coronavirus disease 2019 (COVID-19) infection at the onset of the pandemic has been a crucial challenge in the United States. Anesthesiologists in particular are considered at risk, since aerosol-generating procedures, such as intubation and extubation, have been shown to significantly increase the odds for respiratory infections during severe acute respiratory syndrome (SARS) outbreaks. This study assessed the incidence of COVID-19-like symptoms and the presence of COVID-19 antibodies after work-related COVID-19 exposures, among physicians working in a large academic hospital in New York City (NYC). METHODS: An e-mail survey was addressed to anesthesiologists and affiliated intensive care providers at Columbia University Irving Medical Center on April 15, 2020. The survey assessed 4 domains: (1) demographics and medical history, (2) community exposure to COVID-19 (eg, use of NYC subway), (3) work-related exposure to COVID-19, and (4) development of COVID-19-like symptoms after work exposure. The first 100 survey responders were invited to undergo a blood test to assess antibody status (presence of immunoglobulin M [IgM]/immunoglobulin G [IgG] specific to COVID-19). Work-related exposure was defined as any episode where the provider was not wearing adequate personal protective equipment (airborne or droplet/contact protection depending on the exposure type). Based on the clinical scenario, work exposure was categorized as high risk (eg, exposure during intubation) or low risk (eg, exposure during doffing). RESULTS: Two hundred and five health care providers were contacted and 105 completed the survey (51%); 91 completed the serological test. Sixty-one of the respondents (58%) reported at least 1 work-related exposure and 54% of the exposures were high risk. Among respondents reporting a work-related exposure, 16 (26.2%) reported postexposure COVID-19-like symptoms. The most frequent symptoms were myalgia (9 cases), diarrhea (8 cases), fever (7 cases), and sore throat (7 cases). COVID-19 antibodies were detected in 11 of the 91 tested respondents (12.1%), with no difference between respondents with (11.8%) or without (12.5%) a work-related exposure, including high-risk exposure. Compared with antibody-negative respondents, antibody-positive respondents were more likely to use NYC subway to commute to work and report COVID-19-like symptoms in the past 90 days. CONCLUSIONS: In the epicenter of the United States' pandemic and within 6-8 weeks of the COVID-19 outbreak, a small proportion of anesthesiologists and affiliated intensive care providers reported COVID-19-like symptoms after a work-related exposure and even fewer had detectable COVID-19 antibodies. The presence of COVID-19 antibodies appeared to be associated with community/environmental transmission rather than secondary to work-related exposures involving high-risk procedures.
引用
- Morcuende M, Guglielminotti J, Landau R, et al. Anesthesiologists' and Intensive Care Providers' Exposure to COVID-19 Infection in a New York City Academic Center: A Prospective Cohort Study Assessing Symptoms and COVID-19 Antibody Testing. Anesth Analg. 2020. PMID: 32520728. doi:10.1213/ANE.0000000000005056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。